walk into a bar...they have a drink...when leaving the bartender asks - 'who is going to pay the bill ?' They all look at each other and say - 'hmm..we don't remember'.
for those interested in buying AVXL, buy it after earnings....small bio stocks always tend to sell off with earnings, due to losses, small cash holdings etc. AVXL was down 10% after earnings in Feb.
georgejil this is a chemistry symposium...I seriously doubt any results will be presented at this meeting. look it up. Plus he is presenting with host of other non-avxl folks.
good luck and GOD bless !
this is even lower than LNKD earnings, even after their big selloff last qtr. Don't know why people say FB is overvalued...for its growth it is not expensive at all.
data means nothing without phase2/3 placebo completed...and that WILL take $$ which company does not have. They are also starting Phase 2 Rett, for which they don't have the $$.
These patient news from Aust, Mr. McFarlane is not going to help...you can see the results, stock is back under $5.
so data, patient news, McFarlane blabbering will not help. ONLY thing will move stock is funding via partnership, which they seem to not be able to get.
it is NOT a scientific conference,....it is a chemistry meeting. Look it up. THERE WILL BE NO DATA COMING HERE.
 Earnings next few days....will again show very little cash in hand.
 Chemistry meeting May 17th is NOT going to have any trial data...think everyone knows that.
They need partnership pronto. I don't think any wk12 data will also help, as without partnership how can they even go into Phase 2/3 ?
Some company can pay 100% and still get it cheap
In 5 months ENDP will not be a stand alone company...there will be M&A, consolidation in the pharma space given most companies are down so much they are cheap. M&A will create better synergies and better value, better pricing and CEOs know that.
With M&A ENDP stock will be double of about $27...so target is correct.
yet VRX has so many other issues...sec investigating, senate, jacking up prices, accounting practices.
Endo has none of this. Much cleaner company, with robust pipeline.
incredible beatdown mean strong rebound...even if the just meet the numbers. But again they really lowered it, so beating is going to be easy.
book value so low. Its book value is DOUBLE current price. This is just crazy.
Now at 0.5 times book value, this will be easily and quickly bought out. It has over 100 products in pipeline over next 2-3 years.
CEO needs to buy shares, so do directors.
CEO needs to start looking at strategic - look for suitors, mergers. At 0.5 book value, this is too cheap and a robust pipeline later this year. He already said board is investor friendly. More generic drug companies needs to merge.
some stats -
price/book value - 0.5
price/sales - 1
P/E for next year - 2.7
This is CRAZY !!! vrx is overvalued compared this this much more.
hopefully he is happy.
price to book under 0.5, book value is over $26. Someone will scoop them up quick.